Clinical Read2026-06-15

Lisaftoclax - (GLORA)

Ascentage Pharma Group InternationalAAPG
Indication
Relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Stage
phase2
Event
Phase 2